In the future, by locally administering therapeutic cervical cancer vaccines to induce local immune responses, the progression of CIN can be prevented and its regression promoted (53, 54).The effectiveness of such induction may be evaluated by monitoring changes in local vaginal CD4, CD8, and IL-10 levels. The gene discussed is IL10; the disease is cervical squamous intraepithelial neoplasia.